California State Teachers Retirement System Sells 2,366 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)

California State Teachers Retirement System lessened its position in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 18.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,570 shares of the company’s stock after selling 2,366 shares during the quarter. California State Teachers Retirement System’s holdings in Tyra Biosciences were worth $147,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Polar Asset Management Partners Inc. boosted its stake in shares of Tyra Biosciences by 26.1% during the fourth quarter. Polar Asset Management Partners Inc. now owns 111,107 shares of the company’s stock valued at $1,544,000 after purchasing an additional 23,007 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Tyra Biosciences by 41.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,635 shares of the company’s stock valued at $495,000 after buying an additional 10,426 shares during the last quarter. Vestal Point Capital LP purchased a new stake in shares of Tyra Biosciences during the fourth quarter valued at about $13,761,000. Squarepoint Ops LLC purchased a new stake in shares of Tyra Biosciences during the fourth quarter valued at about $253,000. Finally, Two Sigma Advisers LP acquired a new position in shares of Tyra Biosciences during the fourth quarter valued at about $171,000. Institutional investors own 84.14% of the company’s stock.

Analyst Ratings Changes

TYRA has been the subject of a number of recent research reports. Wedbush reissued an “outperform” rating and set a $30.00 price target on shares of Tyra Biosciences in a research report on Friday, March 28th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a research note on Monday, March 31st. Finally, Piper Sandler assumed coverage on shares of Tyra Biosciences in a research note on Wednesday, May 21st. They issued an “overweight” rating and a $33.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $30.83.

Tyra Biosciences Stock Up 1.5%

Shares of TYRA opened at $10.33 on Friday. Tyra Biosciences, Inc. has a 52-week low of $6.42 and a 52-week high of $29.60. The firm’s fifty day moving average is $9.50 and its two-hundred day moving average is $12.02. The stock has a market cap of $548.42 million, a PE ratio of -6.42 and a beta of 1.07.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. As a group, research analysts anticipate that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.